Clinical trial
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for…
NCT00459277 · Archimedes Development Ltd, Industry · Completed
Key facts
| NCT number | NCT00459277 |
|---|---|
| Title | Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids |
| Official title | A Multicenter, Placebo-Controlled, Double-Blind, Two-Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy |
| Lead sponsor | Archimedes Development Ltd, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer Pain |
| Intervention type | Drug |
| Interventions | Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray) |
| Enrollment | 73 |
| Start date | Dec 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Apr 11, 2007 |
| Last update posted | Jan 25, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: